ESBATech AG, a leading developer of antibody fragment therapeutics, today announced the initiation of a Phase IIa study in patients with acute anterior uveitis. This study is designed to evaluate the safety, tolerability, and clinical activity of topically applied ESBA105 in uveitis pati...
Dr. Urech commented, "ESBATech's proprietary, repeatable screening platform was employed and generated multiple promising antibody fragment product candidates against several targets for topical ophthalmic use. Antibody fragments have a number of advantages over whole antibo...
京东是国内专业的Esbori休闲棉袜网上购物商城,本频道提供Esbori休闲棉袜型号、Esbori休闲棉袜规格信息,为您选购Esbori休闲棉袜型号规格提供全方位的价格参考,提供愉悦的网上购物体验!
ESBATech's successful screening and characterization of all 1.5 million naturally occurring antibody fragment frameworks resulted in highly-stable, single-chain antibody fragments. These drug-like fragments are ideal for pioneering therapeutic interventions that require high ...